Wesper Advances GLP-1 Sleep Apnea Testing and Enables Personalized Treatment

NEW YORK, Feb. 11, 2025 /PRNewswire/: Wesper, a leader in advanced home sleep apnea testing (HSAT), is changing how obesity and sleep apnea are managed by integrating biometric sleep data with metabolic health innovations. Following the FDA approval of GLP-1 receptor agonists for sleep apnea treatment, Wesper is working with hospitals and physicians to bridge the gap between obesity, diabetes, GLP-1 medications, and sleep apnea.
In a recent study, Wesper revealed how obesity, gender, and age interact to influence key sleep apnea metrics, including the Apnea-Hypopnea Index (AHI) and Hypoxic Burden (HB). Hypoxic Burden, a metric measuring cumulative oxygen deprivation during sleep, has emerged as an important predictor of cardiovascular risk in people with sleep apnea. Wesper's findings show how its testing can help healthcare providers diagnose and manage obesity-related sleep apnea, particularly for patients undergoing GLP-1 therapy.
The study analyzed 1,364 patients, including mixed-BMI and obese-only groups, uncovering how factors like weight gain, aging, and gender amplify sleep apnea severity. Among the most significant insights was the heightened impact of weight and age on AHI and HB, with male patients showing considerably higher risks.
Key Findings
- Obesity Worsens Sleep Apnea: For every 1-unit increase in BMI (e.g., going from a BMI of 30 to 31), patients experienced 1 additional breathing interruption per hour during sleep.
- Age Magnifies Sleep Apnea: Each additional year of age increased breathing interruptions by 0.32 events per hour in the mixed-BMI group and by 0.42 events per hour in the obese-only group, showing a greater impact in those with higher BMIs.
- Men Face Greater Risks: Men consistently exhibited more severe sleep apnea than women. In the obese group, males experienced 14 more breathing interruptions per hour and endured 34% more oxygen deprivation during sleep compared to females, despite having similar BMIs.
"Obesity and sleep apnea are intricately linked, and our findings emphasize the unique risks patients face based on their weight, age, and gender," said Dr. Amir Reuveny, CEO and Founder of Wesper. "Wesper's advanced sleep testing system equips providers with the data they need to deliver personalized care, particularly for patients on GLP-1 therapies."
The Link Between GLP-1 Medications and Sleep Apnea
GLP-1 receptor agonists, like semaglutide, have changed weight loss and metabolic care. However, untreated sleep apnea can undermine the benefits of GLP-1 therapy. Intermittent oxygen deprivation and poor-quality sleep caused by sleep apnea may counteract the cardiovascular and metabolic improvements achieved with GLP-1 medications.
Wesper's AI-powered HSAT system addresses this gap by providing high-resolution, multi-night recording. Wesper devices show over 95% AHI correlation to in-lab PSG (Sleep Medicine 2025; JCSM 2023), and the system also tracks advanced metrics like Hypoxic Burden. This lets providers manage obesity and sleep apnea together.
With its patient-friendly design and focus on integrating sleep health into chronic disease care, Wesper supports providers who manage obesity and sleep apnea.
About Wesper
Wesper develops FDA-cleared home sleep testing medical devices used by clinicians. Wesper devices show over 95% AHI correlation to in-lab PSG (Sleep Medicine 2025; JCSM 2023), with AI-driven insights and multi-night data. Wesper helps providers deliver efficient, personalized care for patients with sleep apnea and related conditions. Providers can learn more on the Wesper professional page.
This article is for general information and is not medical advice. Talk to a healthcare provider about your sleep health.



